[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, writes for us a couple times a month on medicine and health issues. He is not a physician, but explains the science and the data well, and helps provide some background understanding and perspective that often benefits both investors and folks who are attentive […]
A few sharp-eyed readers have asked about a teaser ad now circulating from Bill Patalon, and that headline is taken from the ad — a few other stocks are teased as hot “secret” recommendations of Patalon’s Private Briefing service, but it’s that “biggest medical breakthrough of the decade” bit that seems to be catching the […]
This is one of the shorter teaser pitches I’ve ever covered — so, bonus for you, it’s also likelier to be one of my shorter articles! The spiel is an ad for Bill Patalon’s Private Briefing, which is one of those “greatest hits” newsletters … it’s intended to cherry-pick the “best” ideas from all the […]
Comments
$BIOC I haven't seen it discussed on these pages previously, but it looks to me like TrovaGene ($TROV), a competitor of...
Hi wild man: My take on Trovagene ($TROV) is that it's not a bad place to be. Its undervalued here, though getting hemme...
I am having some really good luck with TROVAGENE TROV. Does anybody happen to know why? i bought without wait and see (...
Not that familiar with these companies except for TROVAGENE (TROV). James Altucher follows a few people into companie...
I would like to express my appreciation for the advice and insight that the medical professionals have being given on th...